• Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 258.17%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.49
▼ -0.02 (-0.57%)

This chart shows the closing price for LGVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Longeveron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LGVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LGVN

Analyst Price Target is $12.50
▲ +258.17% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Longeveron in the last 3 months. The average price target is $12.50, with a high forecast of $12.50 and a low forecast of $12.50. The average price target represents a 258.17% upside from the last price of $3.49.

This chart shows the closing price for LGVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Longeveron.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2023EF Hutton Acquisition Co. IReiterated RatingBuy$12.50Low
1/10/2023EF Hutton Acquisition Co. ILower TargetBuy$20.00 ➝ $12.50Low
3/24/2022Maxim GroupInitiated CoverageBuy$14.00Medium
1/5/2022UBS GroupInitiated CoverageBuyHigh
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/10/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/9/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/8/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/10/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/9/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2023
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/8/2023

Current Sentiment

  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Longeveron logo
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Read More

Today's Range

Now: $3.49
Low: $3.40
High: $3.64

50 Day Range

MA: $3.00
Low: $2.52
High: $4.00

52 Week Range

Now: $3.49
Low: $2.50
High: $7.61

Volume

53,727 shs

Average Volume

111,605 shs

Market Capitalization

$73.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Longeveron?

The following sell-side analysts have issued stock ratings on Longeveron in the last twelve months: EF Hutton Acquisition Co. I.
View the latest analyst ratings for LGVN.

What is the current price target for Longeveron?

1 Wall Street analysts have set twelve-month price targets for Longeveron in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 258.2%. EF Hutton Acquisition Co. I has the highest price target set, predicting LGVN will reach $12.50 in the next twelve months. EF Hutton Acquisition Co. I has the lowest price target set, forecasting a price of $12.50 for Longeveron in the next year.
View the latest price targets for LGVN.

What is the current consensus analyst rating for Longeveron?

Longeveron currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LGVN will outperform the market and that investors should add to their positions of Longeveron.
View the latest ratings for LGVN.

What other companies compete with Longeveron?

How do I contact Longeveron's investor relations team?

Longeveron's physical mailing address is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. The company's listed phone number is 305-302-7158 and its investor relations email address is br[email protected]. The official website for Longeveron is www.longeveron.com. Learn More about contacing Longeveron investor relations.